| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. | Obicetrapib - (OCEAN) | Alzheimer's Disease | Phase 2a | Trial Planned | Oral | Neurology |
| NewcelX Ltd. | Sanorex (mazindol) | Obesity | NDA Filing | oral | Endocrinology | |
| NewcelX Ltd. | Quilience (Mazindol ER) - (AMAZE) | Narcolepsy | Phase 3 | Oral | Neurology | |
| NewcelX Ltd. | Nolazol | ADHD | Phase 2 | Oral | Psychiatric | |
| NewcelX Ltd. | Quilience(R) - (POLARIS) | Narcolepsy | Phase 2a | Oral | Neurology | |
| NextCure Inc. | NC318 + Pembrolizumab | PD-1 axis inhibitor refractory non-small cell lung cancer (NSCLC) | Phase 2 | Ongoing | Intravenous | Oncology |
| NextCure Inc. | NC318 | Solid tumors | Phase 2 | Intravenous | Oncology | |
| NKGen Biotech Inc. | Troculeucel (SNK01) | Alzheimer's Disease | Phase 2 | Data Released | Intravenous | Neurology |